Authors

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP

Latest:

Dr Habib on Developments in Palliative Care For Patients With Cancer

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.

Sonam Puri, MD

Latest:

Dr. Puri on Clinically Relevant Biomarkers in SCLC

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer.

Sherry Shen, MD

Latest:

Dr Shen on Adjuvant CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Sherry Shen, MD, discusses trials evaluating adjuvant CDK4/6 inhibitors in patients with early-stage, HR-positive, HER2-negative breast cancer.

Robert Alter, MD, John Theurer Cancer Center

Latest:

Incorporating Treatment Advances Into mRCC Management

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Katelyn M. Atkins, MD, PhD

Latest:

Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric Cancer

Katelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.

Timothy J. Brown, MD

Latest:

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

Latest:

Key Clinical Data in Relapsed/Refractory CLL

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

Julie K. Heimbach, MD

Latest:

Dr. Heimbach on the Need for Multidisciplinary Care in HCC

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

William M. Sikov, MD

Latest:

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Mustafa Özguröğlu, MD

Latest:

Dr. Ozguroglu on the Individualization of Treatment in NSCLC

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Kathryn C. Arbour, MD

Latest:

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Margaret T. Kasner, MD

Latest:

Practice Pearls for Treatment of Secondary AML in the Community Setting

Panelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.

Makenzi Evangelist, MD

Latest:

Dr. Evangelist on the Goals of the MYLUNG Consortium in Lung Cancer

Makenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.

Helen Moon, MD

Latest:

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

Chiara Cremolini, MD, PhD, University of Pisa

Latest:

Dr Cremolini on the Utility of xM and xM NeXT Personal Dx MRD Assays

Chiara Cremolini, MD, PhD, discusses the use of the xM and NeXT Personal Dx assays in the detection of minimal residual disease in patients with cancer.

Stefan Maksimovic, MD

Latest:

Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCC

Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.

Joanne Kurtzberg, MD

Latest:

Dr. Kurtzberg on Long-term OS for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Joanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.

Jonathan D. Cheng, MD

Latest:

Dr. Cheng on Advances With Immunotherapy-Based Combinations in Oncology

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

Shawna Kraft, PharmD, BCOP

Latest:

Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCC

Shawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).

American Oncology Network

Latest:

American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care Gap

American Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.